过去一年中添加的文章，按日期排序
Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer
H Bai, Y Zhou, W Liu, W Xu, L Cheng, Y Huo, H Ji… - Heliyon, 2024 - cell.com
146 天前 - … In first-generation EGFR-TKIs treatment, gefitinib showed favorable efficacy
compared to icotinib and erlotinib, particularly in patients with EGFR L858R mutations. The …
compared to icotinib and erlotinib, particularly in patients with EGFR L858R mutations. The …
242P Prognostic role of tumor microenvironment features in advanced non-small cell lung cancer molecular subtypes: A multicentric, retrospective study
L Zullo, A Marinello, MR Ghigna, G De Maglio… - ESMO Open, 2024 - esmoopen.com
150 天前 - … This is a three-centers, retrospective study of patients (pts) treated in 2008-2023
for … In EGFR+, 206 pts were analyzed for OS: 67 had first line osimertinib, 115 gefitinib/erlotinib, …
for … In EGFR+, 206 pts were analyzed for OS: 67 had first line osimertinib, 115 gefitinib/erlotinib, …
4CPS-147 Osimertinib: a promising treatment for EGFR mutation-positive non-small-cell lung cancer
RT Bermejo, JCDR Valencia, ME Bosch, AL Higuera - 2024 - ejhp.bmj.com
150 天前 - … NSCLC stage was IV in 100% of patients, 23.1% suffered from brain metastases,
and 79.5% had ECOG-PS 0–1. Patients started treatment with osimertinib as first-line therapy …
and 79.5% had ECOG-PS 0–1. Patients started treatment with osimertinib as first-line therapy …
[PDF][PDF] … of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient
G Suay, F Aparisi, O Juan-Vidal - Chinese Clinical Oncology, 2024 - cdn.amegroups.cn
160 天前 - … Moving to the treatment of patients with molecular alterations… are recommendations
for each line of treatment. In the EGFR … gefitinib and erlotinib in first-line setting. However, no …
for each line of treatment. In the EGFR … gefitinib and erlotinib in first-line setting. However, no …
The importance of re-biopsy in the era of molecular therapy for lung cancer
N Lalić, D Bursać, M Bojović, M Nemet… - Srpski arhiv za …, 2024 - doiserbia.nb.rs
167 天前 - … – first-generation agents like gefitinib and erlotinib, second-generation afatinib, and
introduction of third-generation (osimertinib or lolatinib) when initial treatments are met with …
introduction of third-generation (osimertinib or lolatinib) when initial treatments are met with …
113P The prognostic importance of nutrition and inflammation in advanced lung cancer with actionable mutation
D Bayram, B Bilgin, Ş Yücel - ESMO Open, 2024 - esmoopen.com
179 天前 - … Inclusion criteria; age ≥18 years, Stage 3C-4 patients, … erlotinib/gefitinib in EGFR
mutation patients and crizotinib in ALK rearrangement patients as first or second-line treatment…
mutation patients and crizotinib in ALK rearrangement patients as first or second-line treatment…
Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
P Mahalapbutr, T Rungrotmongkol - Frontiers in Drug Discovery, 2024 - frontiersin.org
180 天前 - … and patients with these mutations can be effectively treated … greater efficacy compared
to gefitinib and erlotinib. On top … treating NSCLC patients with EGFR ex20ins mutations. …
to gefitinib and erlotinib. On top … treating NSCLC patients with EGFR ex20ins mutations. …
[HTML][HTML] Azd9291 inhibitor
J Amri, N Molaee, H Karami, M Baazm - azd9291inhibitor.com
181 天前 - … gefitinib and erlotinib have been extensively applied to the treatment of patients
with … Despite the dramatic efficacy of EGFR-TKIs in NSCLC patients, most patients ultimately …
with … Despite the dramatic efficacy of EGFR-TKIs in NSCLC patients, most patients ultimately …
Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
S Guan, X Chen, Y Wei, F Wang, W Xie, Y Chen… - Clinical Cancer …, 2024 - AACR
188 天前 - … cells after treated with gefitinib (E), erlotinib (F), and osimertinib (G) for 72 hours.
The IC50 of overexpression of USP36 in HCC827 cells after treated with gefitinib (H), erlotinib (I…
The IC50 of overexpression of USP36 in HCC827 cells after treated with gefitinib (H), erlotinib (I…
… zipper downregulated in cancer-1 interacts with clathrin adaptors to control epidermal growth factor receptor (EGFR) internalization and gefitinib response in EGFR …
HN Huang, PF Hung, YP Chen, CH Lee - International Journal of …, 2024 - mdpi.com
188 天前 - … decreased gefitinib and erlotinib sensitivity … gefitinib and erlotinib is the first-line
treatment for patients with NSCLC harboring EGFR M in many countries, 30% to 50% of patients …
treatment for patients with NSCLC harboring EGFR M in many countries, 30% to 50% of patients …